Arctoris
Arctoris is a UK-based Partnership Research Organisation operating the Ulysses® fully robotic, cloud-controlled drug discovery platform, generating AI-ready experimental data for biotech, techbio, pharma, and AI foundation model developers across global markets.
- Company typePrivate
- Founded2018
- HeadquartersOxford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Arctoris does
Arctoris is a UK-based Partnership Research Organisation (PRO) founded in 2018 out of the University of Oxford, providing automated wet lab biology R&D and data generation services to biotech, techbio, and pharmaceutical companies. The company's core offering is the Ulysses® platform — a fully robotic, cloud-controlled drug discovery platform that executes entire assay cascades across biochemistry, biophysics, cell biology, and structural biology, capturing every action, parameter, and datapoint in real time. This platform generates AI/ML-ready, FAIR-compliant structured datasets with up to 100x more datapoints per assay than industry standard, compressing Design-Make-Test-Analyse (DMTA) cycles from weeks to days.
The company monetises through bespoke, multi-year partnership agreements spanning target identification through IND-enabling studies, plus a distinct Foundation Model Data Generation revenue stream serving AI drug discovery labs (including Isomorphic Labs, where Arctoris delivered >2.2M annotated datapoints across 65 targets). Arctoris pursues a direct enterprise field sales motion, working as an extension of partner R&D teams. Customer segments include biotech companies, techbio/AI drug discovery firms, pharmaceutical companies, and increasingly AI foundation model developers. Operations span offices in Oxford (UK headquarters with primary laboratory at 120E Olympic Avenue, Abingdon), Boston (US), and Singapore (APAC hub), with partnership relationships across the US, UK, Germany, Australia, Korea, and China. Key technical metrics include Z' scores consistently above 0.75, assay onboarding in as little as 4 hours, >100 proteins produced with >95% purity, and 12+ biologics guided to IND.
Arctoris firmographics
Firmographics- Name
- Arctoris
- Legal name
- Arctoris Limited
- Website
- https://arctoris.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Arctoris is a UK-based Partnership Research Organisation operating the Ulysses® fully robotic, cloud-controlled drug discovery platform, generating AI-ready experimental data for biotech, techbio, pharma, and AI foundation model developers across global markets.
- Ownership category
- akta.pro rank
Arctoris industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Arctoris is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Arctoris business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Partnership Research Services: Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio and pharma companies. Services span from target identification through IND-enabling studies, generating revenue through project-based and long-term partnership agreements.
- Foundation Model Data Generation: Custom experimental campaigns for AI model training specifically designed to fill gaps in proprietary model knowledge graphs, with data ownership transferred to clients as strategic assets.
- Bespoke Proprietary Training Datasets: Custom experimental campaigns—chemistry, biology or biophysics—specifically designed to fill gaps in model knowledge graphs. Clients own resulting datasets outright as proprietary strategic assets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Bespoke Partnership Research Services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Arctoris product offering
Product offeringCore offering
Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies. The core offering is delivered through Ulysses®, a fully robotic, cloud-controlled drug discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology, generating precise, reproducible, and AI-ready datasets at industrial scale. Services span from target identification through IND-enabling studies via long-term partnership agreements.
Product overview
Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D services. The core offering is the Ulysses® platform, a fully robotic, cloud-controlled discovery platform that executes assay cascades across biochemistry, biophysics, cell biology, and structural biology. This platform is complemented by specialized service modules including Hit Identification, Hit-to-Lead, Lead Optimization, and IND-Enabling Studies, along with Foundation Model Data Generation for AI/ML training. Additional capabilities include Biologics, Protein Science, and a recently launched Biophysics Centre of Excellence providing tenfold expanded biophysical instrumentation capacity. The company generates precise, reproducible, AI-ready datasets at scale for biotech, techbio, and pharma partners.
Differentiator
Problem solved
Functional benefit
Brands
- Ulysses®: Arctoris' fully robotic, cloud-controlled drug discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology
Products and services
- Ulysses® Platform Fully robotic, cloud-controlled drug discovery platform that executes assay cascades across biochemistry, biophysics, cell biology, and structural biology, generating AI-ready datasets with zero human variability through industrial automation; marketed as the world's first fully automated drug discovery platform.
- Hit Identification Fully automated high-throughput screening workflows for rapid identification of high-quality chemical matter from compound libraries, delivered as a partnership research service.
- Hit-to-Lead Deep interrogation of hits through biophysical and cellular assays to identify and prioritize true leads with precision kinetic and thermodynamic characterization, delivered as a partnership research service.
- Lead Optimization Integrated multimodal workflows optimizing efficacy, safety, and developability with mechanistic profiling across concentration ranges; reduces lead optimization timelines by up to 30%.
- IND-Enabling Studies Support Comprehensive preclinical support including functional characterization, PK/PD studies, GMP-adjacent protein production, and regulatory planning; supported 12+ IND filings.
- Foundation Model Data Generation High-fidelity dataset generation service for training and fine-tuning AI foundation models; delivered over 2.2M annotated datapoints for Isomorphic Labs across 65 targets with datasets outperforming CRO and public data benchmarks.
- Cell Biology Services Comprehensive cell-based assays including target engagement, phenotypic screening, high-content imaging, and flow cytometry; supports patient-derived models and 3D cultures for predictive drug discovery.
- Biochemistry & Enzymology Services High-throughput biochemical assays, enzymatic profiling, and kinetic analysis; delivers Z' scores above 0.75 consistently, with capacity for 2,000+ compounds per day throughput.
- Biophysics Services Quantitative analysis of protein-ligand interactions including SPR, ITC, and thermodynamic profiling; enables high-throughput kinetic characterization across large compound libraries.
- Structural Biology Services High-throughput X-ray crystallography, cryo-EM, and computational modeling; solved over 200 protein-ligand complex structures with processing capacity for 300+ ligands.
- Protein Science Services Recombinant protein expression, purification, and characterization across multiple host systems (E. coli, insect, mammalian); produced over 100 proteins with purity exceeding 95%.
- Biologics Services Antibody discovery, engineering, and functional characterization for biologics including bispecifics, peptides, and RNA therapeutics; guided over 12 biologic candidates into clinical trials.
- Data Science & Informatics Integrated analytics platform providing real-time QC, kinetic modeling, curve fitting (IC50, EC50, Kd), and ML model training support; delivers FAIR-compliant, AI/ML-ready structured datasets.
- Biophysics Centre of Excellence Major infrastructure expansion providing tenfold increase in biophysical instrumentation capacity, addressing bottlenecks in experimental validation for AI-driven drug discovery.
Quantifiable outcome
- Z' scores consistently above 0.75 in high-throughput screens; Z' values of 0.8 and higher regularly achieved in closed-loop studies
- +6 more outcomes
Companies that use Arctoris
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles4 records
Arctoris technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability13 records
Feature7 records
Arctoris partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Alithea GenomicscoreCollaboration integrating MERCURIUS 1536 DRUG-seq whole-transcriptome profiling with Arctoris' automated workflows. Supports upstream cell preparation, compound dosing, and sample preparation in 1536-well format for scalable phenotypic screening.
- 310.aicoreBreakthrough collaboration validating first de novo protein from MP4 platform that binds ATP for heart failure treatment. Arctoris used Ulysses automation platform for protein expression, purification, and biophysical validation confirming folding, purity, and ATP-binding activity.
- University of Cambridge and King's College LondoncoreResearch collaboration demonstrating AI systems can actively generate therapeutic hypotheses. AI identified combinations of non-cancer drugs targeting breast cancer cells; Arctoris provided automated experimental validation creating closed-loop system with Z' values of 0.8+.
- Evariste TechnologiescoreAI drug discovery partnership combining Arctoris' wet lab data generation with Evariste's ML-enabled molecular design. Progressed from target selection to several qualified lead series in non-small cell lung cancer within six months.
- Isomorphic LabscoreFoundation model data generation partnership (Project Tiger). Delivered >2.2M annotated datapoints over 65 targets for training generative drug design models. Datasets yielded significantly superior model performance vs CRO and public data, underpinning clinical candidates progressing in 2025.
- Intelligent OMICScoreInnovate UK-backed project combining AI, machine learning and automated biology for lung cancer drug discovery targeting KRAS signalling pathway. Intelligent OMICS provides in silico target identification; Arctoris runs biological assay validation using automated platform.
- Medicines Discovery CatapultcorePartner in Innovate UK-backed lung cancer project contributing cheminformatics expertise to identify appropriate chemical tools and leads for newly uncovered targets.
- IBM ResearchcoreCollaboration advancing fully autonomous closed-loop molecular discovery targeting Janus kinase (JAK) proteins. Integrates computational molecular design, automated synthesis, and experimental testing into continuous DMTA cycle. Arctoris' Ulysses platform combined with IBM's automated small molecule synthesis capabilities.
- MoleculeminorCollaboration combining Arctoris' automated laboratory infrastructure with Molecule's open-source software platform for drug intellectual property sharing. Aims to reduce legal and financial barriers in collaborative drug discovery.
- Insilico MedicinecoreTechnology partnership for AI-guided drug discovery against COVID-19, spanning target identification and generative chemistry. Insilico's AI capabilities combined with Arctoris' robotic platform for rapid evaluation of novel JAK inhibitors. Partnership extended through BioTarget Cancer Research UK initiative for oncology.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Arctoris competitors and assessment
Company assessmentDirect peers
- Strateos: Cloud-based automated laboratory platform enabling remote-controlled experiments for drug discovery. Operates a similar partnership model providing automated wet-lab data generation services to biotech and pharma customers.
- Emerald Cloud Lab: Cloud-controlled, fully automated laboratory facility providing remote experimental execution and data generation services. Directly comparable to Arctoris's Ulysses platform in terms of robotic lab infrastructure and service delivery model.
- Insilico Medicine: AI-driven drug discovery company combining generative AI with experimental validation. Comparable as a direct customer/partner of Arctoris with overlapping AI drug discovery mission and partnership-based commercial model.
Broad incumbents
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML for pharma partnerships. Comparable as an AI drug discovery peer, though significantly larger and with in-house automated lab capabilities rather than pure service model.
- Insitro: Machine learning-driven drug discovery company combining proprietary data generation with ML models for pharma partnerships. Comparable as an AI drug discovery peer with experimental data generation capabilities and pharma partnership model.
- Benchling: Cloud-based life sciences R&D platform providing informatics and data management for biotech R&D. Adjacent peer providing laboratory informatics infrastructure, though focused on software rather than automated experimental execution.
- Schrödinger: Computational drug discovery platform combining physics-based simulation with ML for pharma partnerships. Comparable as a technology-enabled drug discovery company serving pharma, though primarily computational rather than experimental automation.
Emerging players
- LabGenius: Machine learning-driven antibody discovery company using automated laboratory robotics. Comparable as a UK-based ML-driven biotech using automation, though focused specifically on biologics rather than small molecules and services.
- Culture Biosciences: Cloud-based bioprocess development platform providing automated fermentation and cell culture services. Comparable as a cloud-lab automated services provider, though focused on bioprocess rather than drug discovery.
- Synthace: Cloud-based laboratory automation platform enabling experimental design and execution for life science R&D. Comparable as a lab automation platform serving biotech R&D, though focused on software infrastructure rather than full-service execution.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Arctoris social profiles
Digital presenceArctoris compliance and trust
Trust signalCompliance1 record
Arctoris financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arctoris leadership team
Management profileNumber of profiles
Profiles8 records
Arctoris funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arctoris M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arctoris
What does Arctoris do?
Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies. The core offering is delivered through Ulysses®, a fully robotic, cloud-controlled drug discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology, generating precise, reproducible, and AI-ready datasets at industrial scale. Services span from target identification through IND-enabling studies via long-term partnership agreements.
Is Arctoris a public or private company?
Arctoris is a private company. It is classified as venture growth investor backed and is currently operating.
When was Arctoris founded?
Arctoris was founded in 2018. It employs 11 to 50 people.
Where is Arctoris based?
Arctoris is headquartered in Oxford, United Kingdom, in the Europe region.
How does Arctoris make money?
Three revenue lines are on record. Partnership Research Services are the primary driver. The others are foundation Model Data Generation and bespoke Proprietary Training Datasets.
Who are Arctoris's main competitors?
Direct peers on record are Strateos, Emerald Cloud Lab and Insilico Medicine. Broad incumbents are Recursion Pharmaceuticals, Insitro, Benchling and Schrödinger. Emerging players are LabGenius, Culture Biosciences and Synthace.
Does Arctoris have an API?
No public API is recorded for Arctoris.
What industry is Arctoris in?
Arctoris's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAIAD, Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations). Its NAICS code is 541714 and its SIC code is 8731.